Skip to main content

Table 2 Cutaneous adverse reactions during lithium treatment: randomized clinical trials

From: Cutaneous adverse reaction during lithium treatment: a case report and updated systematic review with meta-analysis

Study

Number of patients

Diagnosis

Duration of lithium treatment

Outcome measured

Follow-up

Results

Goodwin et al. (2004)

167 (166 completed) lithium

280 (227 completed) lamotrigine

191 (190 completed) placebo

BD1

NA

Self-reported incidence of new-onset skin disorders during treatment

18-months

Lithium: 5%

Lamotrigine: 7%

Placebo: 5%

Geller et al. (2012)

89 risperidone

90 (84 completed) lithium

100 (97 completed) valproic acid

BD1

NA

Systematic structured assessment of side effects

8 weeks

Lithium: 6%

Risperidone: 6.7%

Valproic acid: 13.4%

NCT01189812

40 citalopram + placebo

40 citalopram + lithium

MDD, Dysthymia

DNOS, BPD

4 weeks

Self-reported incidence of new-onset skin disorders during treatment

4 weeks

Citalopram + lithium: 2.5%

Citalopram + placebo: 2.5%

  1. NA not available, BD bipolar disorder, BD1 bipolar disorder type 1, MDD major depressive disorder, DNOS depression not otherwise specified, BPD borderline personality disorder